Cipla Ltd - Launch of generic Nintedanib - Angel Broking

Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

"Cipla Limited announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet another milestone in Cipla's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people. Cipla's journey in IPF began in 2010 with the introduction of Pirfenex, the world's first generic Pirfenidone and the first ever approved drug for IPF in India. Cipla's Nintib is priced at Rs. 69 (100 mg) and Rs. 85 (150 mg) per capsule. IPF is a chronic progressive form of lung disease with an average survival rate of three to five years if left untreated. It is characterized by scarring in the lungs, wherein the lung tissue becomes stiff and thick. This interferes with a person's ability to breathe and reduces oxygen supply to the blood, resulting in shortness of breath. This is positive development for the company."

Shares of CIPLA LTD. was last trading in BSE at Rs.764.05 as compared to the previous close of Rs. 763.85. The total number of shares traded during the day was 220330 in over 6139 trades.

The stock hit an intraday high of Rs. 774.3 and intraday low of 756.45. The net turnover during the day was Rs. 168882484.

Source : Equity Bulls

Keywords